A Multi-Center, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927, an Immunotherapy, in Subjects With Advanced Solid Tumors

Trial Profile

A Multi-Center, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927, an Immunotherapy, in Subjects With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs ABBV 927 (Primary) ; ABBV 927 (Primary) ; Nivolumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AbbVie
  • Most Recent Events

    • 31 Oct 2017 Planned End Date changed from 1 Sep 2019 to 30 Dec 2019.
    • 28 Jun 2017 Planned End Date changed from 12 Feb 2022 to 1 Sep 2019.
    • 13 Apr 2017 Planned End Date changed from 1 Apr 2019 to 1 Feb 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top